These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 9213175)

  • 1. Interstitial pneumonitis related to granulocyte colony-stimulating factor administration following chemotherapy for elderly patients with non-Hodgkin's lymphoma.
    Hasegawa Y; Ninomiya H; Kamoshita M; Ohtani K; Kobayashi T; Kojima H; Nagasawa T; Abe T
    Intern Med; 1997 May; 36(5):360-4. PubMed ID: 9213175
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of delayed granulocyte colony-stimulating factor after full dose CHOP therapy in non-Hodgkin's lymphoma: a pilot study for a leukocyte count oriented regimen.
    Sawada KI; Sato N; Kohno M; Hannda H; Yasukouchi T; Tanngo M; Hirayama A; Koike T
    Leuk Lymphoma; 1995 Dec; 20(1-2):103-9. PubMed ID: 8750630
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mobilization of peripheral blood progenitor cells following CHOP treatment combined with delayed granulocyte colony-stimulating factor administration in patients with non-Hodgkin's lymphoma.
    Takano H; Sawada K; Sato N; Natoya A; Tarumi T; Hirayama S; Koizumi K; Takahashi TA; Sekiguchi S; Koike T
    Leuk Lymphoma; 1996 May; 21(5-6):473-8. PubMed ID: 9172813
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Addition of rituximab to cyclophosphamide, doxorubicin, vincristine, and prednisolone therapy has a high risk of developing interstitial pneumonia in patients with non-Hodgkin lymphoma.
    Katsuya H; Suzumiya J; Sasaki H; Ishitsuka K; Shibata T; Takamatsu Y; Tamura K
    Leuk Lymphoma; 2009 Nov; 50(11):1818-23. PubMed ID: 19863173
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pulmonary toxicity after granulocyte colony-stimulating factor-combined chemotherapy for non-Hodgkin's lymphoma.
    Yokose N; Ogata K; Tamura H; An E; Nakamura K; Kamikubo K; Kudoh S; Dan K; Nomura T
    Br J Cancer; 1998 Jun; 77(12):2286-90. PubMed ID: 9649147
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-benefit of granulocyte colony-stimulating factor administration in older patients with non-Hodgkin's lymphoma treated with combination chemotherapy.
    Zagonel V; Babare R; Merola MC; Talamini R; Lazzarini R; Tirelli U; Carbone A; Monfardini S
    Ann Oncol; 1994; 5 Suppl 2():127-32. PubMed ID: 7515645
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low-dose granulocyte colony-stimulating factor overcomes neutropenia in the treatment of non-Hodgkin's lymphoma with higher cost-effectiveness.
    Hara T; Tsurumi H; Kasahara S; Kanemura N; Yoshikawa T; Goto N; Kojima Y; Yamada T; Sawada M; Takahashi T; Oyama M; Tomita E; Moriwaki H
    Int J Hematol; 2005 Dec; 82(5):430-6. PubMed ID: 16533747
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of granulocyte colony-stimulating factor administration in elderly patients with aggressive non-Hodgkin's lymphoma treated with a pirarubicin-combination chemotherapy regimen. Groupe d'Etudes des Lymphomes de l'Adulte.
    Guerci A; Lederlin P; Reyes F; Bordessoule D; Sebban C; Tilly H; Kerneis Y; Biron P; Gisselbrecht C; Herbrecht R; Coiffier B
    Ann Oncol; 1996 Nov; 7(9):966-9. PubMed ID: 9006749
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-dose CHOP as initial therapy for patients with poor-prognosis aggressive non-Hodgkin's lymphoma: a dose-finding pilot study.
    Shipp MA; Neuberg D; Janicek M; Canellos GP; Shulman LN
    J Clin Oncol; 1995 Dec; 13(12):2916-23. PubMed ID: 8523055
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mobilization of peripheral blood stem cells by granulocyte-colony stimulating factors: comparison of a standard dose of glycosylated and mutated granulocyte-colony stimulating factor in non-Hodgkin's lymphoma patients following CHOP therapy.
    Takemoto Y; Wada H; Takatsuka H; Okamoto T; Kakishita E
    Drugs Exp Clin Res; 2000; 26(1):1-5. PubMed ID: 10761530
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elderly patients with aggressive non-Hodgkin's lymphoma treated with CHOP chemotherapy plus granulocyte-macrophage colony-stimulating factor: identification of two age subgroups with differing hematologic toxicity.
    Gómez H; Mas L; Casanova L; Pen DL; Santillana S; Valdivia S; Otero J; Rodriguez W; Carracedo C; Vallejos C
    J Clin Oncol; 1998 Jul; 16(7):2352-8. PubMed ID: 9667250
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Neutrophil functions during treatment with granulocyte colony-stimulating factor (G-CSF) in the elderly with non-Hodgkin's lymphoma: including two patients accompanied with interstitial pneumonitis during the treatment with G-CSF].
    Katoh M; Shikoshi K; Takada M; Umeda M; Tsukahara T; Shirai T
    Nihon Ronen Igakkai Zasshi; 1993 Nov; 30(11):953-7. PubMed ID: 7507533
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CHOP compared with CHOP plus granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin's lymphoma.
    Doorduijn JK; van der Holt B; van Imhoff GW; van der Hem KG; Kramer MH; van Oers MH; Ossenkoppele GJ; Schaafsma MR; Verdonck LF; Verhoef GE; Steijaert MM; Buijt I; Uyl-de Groot CA; van Agthoven M; Mulder AH; Sonneveld P
    J Clin Oncol; 2003 Aug; 21(16):3041-50. PubMed ID: 12915593
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidence of interstitial pneumonitis in non-Hodgkin's lymphoma patients receiving immunochemotherapy with pegylated liposomal doxorubicin and rituximab.
    Zhou T; Shen Q; Peng H; Chao T; Zhang L; Huang L; Yang K; Thapa S; Yu S; Jiang Y
    Ann Hematol; 2018 Jan; 97(1):141-147. PubMed ID: 29086009
    [TBL] [Abstract][Full Text] [Related]  

  • 15. G-CSF use in patients receiving first-line chemotherapy for non-Hodgkin's lymphoma (NHL) and granulocyte-colony stimulating factors (G-CSF) as observed in clinical practice in Italy.
    Vitolo U; Angrili F; DeCosta L; Wetten S; Federico M
    Med Oncol; 2016 Dec; 33(12):139. PubMed ID: 27822615
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of recombinant granulocyte colony-stimulating factor (G-CSF) in patients treated with ProMACE-CytaBOM for HIV-related non-Hodgkin's lymphoma (NHL).
    Rossi G; Donisi A; Casari S; Re A; Stellini R; Cadeo G; Carosi G
    Haematologica; 1998 Apr; 83(4):317-22. PubMed ID: 9592981
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase I trial of standard and cyclophosphamide dose-escalated CHOP with granulocyte colony stimulating factor in elderly patients with non-Hodgkin's lymphoma.
    Meyer RM; Gyger M; Langley R; Lespérance B; Caplan SN
    Leuk Lymphoma; 1998 Aug; 30(5-6):591-600. PubMed ID: 9711921
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Recombinant G-CSF and the interstitial pneumonia during MACOP-B therapy in two cases of non-Hodgkin's lymphoma].
    Okubo Y; Nakazawa K
    Rinsho Ketsueki; 1993 Apr; 34(4):473-7. PubMed ID: 7685433
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of age group on febrile neutropenia risk assessment and management in patients with diffuse large B-cell lymphoma treated with R-CHOP regimens.
    Lugtenburg P; Silvestre AS; Rossi FG; Noens L; Krall W; Bendall K; Szabo Z; Jaeger U
    Clin Lymphoma Myeloma Leuk; 2012 Oct; 12(5):297-305. PubMed ID: 23040435
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CHOP versus CHOP plus granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin's lymphoma.
    Alliot C
    J Clin Oncol; 2005 Jul; 23(21):4797-9; author reply 4799-800. PubMed ID: 16034060
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.